0
     

Report Added
Report already added
Trigeminal Neuralgia (Tic Douloureux) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Trigeminal Neuralgia (Tic Douloureux) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 1, 3, 2, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Trigeminal Neuralgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trigeminal Neuralgia (Tic Douloureux) - Overview
Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigeminal Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development
Acasti Pharma Inc
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Coda Biotherapeutics Inc
Hoba Therapeutics ApS
Initiator Pharma AS
InMed Pharmaceuticals Inc
Noema Pharma AG
Noveome Biotherapeutics Inc
OliPass Corporation
Oxford Cannabinoid Technologies Ltd
Praxis Precision Medicines Inc
USA Elixiria Biotech Inc
Trigeminal Neuralgia (Tic Douloureux) - Drug Profiles
basimglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
DKI-561 - Drug Profile
Product Description
Mechanism Of Action
ELB-00824 - Drug Profile
Product Description
Mechanism Of Action
erenumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
GTX-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HB-086 - Drug Profile
Product Description
Mechanism Of Action
INM-405 - Drug Profile
Product Description
Mechanism Of Action
IPTN-2021 - Drug Profile
Product Description
Mechanism Of Action
OCT-130401 - Drug Profile
Product Description
Mechanism Of Action
OLP-1002 - Drug Profile
Product Description
Mechanism Of Action
PRAX-562 - Drug Profile
Product Description
Mechanism Of Action
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
ST-266 - Drug Profile
Product Description
Mechanism Of Action
vixotrigine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects
Trigeminal Neuralgia (Tic Douloureux) - Product Development Milestones
Featured News & Press Releases
Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Feb 14, 2022: Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Oct 11, 2021: Oxford Cannabinoid Technologies targets chronic pain condition with latest formulation
Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Acasti Pharma Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Coda Biotherapeutics Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Hoba Therapeutics ApS, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Initiator Pharma AS, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noema Pharma AG, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noveome Biotherapeutics Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Oxford Cannabinoid Technologies Ltd, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Praxis Precision Medicines Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Pipeline by USA Elixiria Biotech Inc, 2022
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, 2022

List of Figures
Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Trigeminal Neuralgia (Tic Douloureux) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW